| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H21NO4 |
| Molecular Weight | 351.3957 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C2=C(C=C(OC(C)=O)C=C2)C(C)=C1C3=CC=C(OC(C)=O)C=C3
InChI
InChIKey=KSZGVNZSUJHOJA-UHFFFAOYSA-N
InChI=1S/C21H21NO4/c1-5-22-20-11-10-18(26-15(4)24)12-19(20)13(2)21(22)16-6-8-17(9-7-16)25-14(3)23/h6-12H,5H2,1-4H3
| Molecular Formula | C21H21NO4 |
| Molecular Weight | 351.3957 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Zindoxifene (D 16726 or 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole), is an antiestrogenic phenylindole with a high affinity for the estrogen receptor. Zindoxifene exerts inhibiting activity against tumors of prostatic and mammary origins both in vitro and in vivo. It was in phase I/II study for the treatment of advanced breast cancer. Zindoxifene development has been discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
